Provider Summary
Primary Uses
Add-on maintenance treatment of severe eosinophilic asthma in adults meeting criteria.
Mechanism of Action
Anti‑IL‑5 monoclonal antibody reduces eosinophil production and survival.
Pre-treatment / Baseline Requirement
Confirm eosinophilic phenotype and uncontrolled severe asthma; baseline CBC with eosinophils often used; treat pre-existing helminth infections before initiation per PI; monitor during and after infusion.
Common side effects
Oropharyngeal pain; may also include fatigue or muscle pain.
Serious adverse effects / key risks
Boxed warning: anaphylaxis; hypersensitivity reactions.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Add-on maintenance treatment of severe eosinophilic asthma in adults meeting criteria.
How it works
Anti‑IL‑5 monoclonal antibody reduces eosinophil production and survival.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Oropharyngeal pain; may also include fatigue or muscle pain.
Get urgent help for:
Boxed warning: anaphylaxis; hypersensitivity reactions.
On treatment Day:
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.